ALISA BLOUNT VON RIOTTE MD
Prescription History 1932201670
Psychiatry & Neurology - Psychiatry in Provo, UT

NPI Status: Active since September 02, 2006

Contact Information

1300 E CENTER ST
SOUTHEAST UNIT
PROVO, UT
ZIP 84606
Phone: (801) 344-4400
Fax: (801) 344-4325

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ALISA BLOUNT VON RIOTTE MD, an active Psychiatry specialist practicing in Provo, UT. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 36 documented patient claims. Among these therapy options, the most frequently utilized medication is Invega Sustenna, which accounts for 19 claims alone.

Medication Index

No matching medications currently found on file.

Benztropine Mesylate

Generic Formulation: Benztropine MesylateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 243
UT State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills52.1
Peer Average Days Supply1,417
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.0% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $91.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.41

State Avg Cost Per Claim

$12.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Therapeutic Applications

Benztropine is used to treat symptoms of Parkinson's disease or involuntary movements due to the side effects of certain psychiatric drugs (antipsychotics such as chlorpromazine/haloperidol). Benztropine belongs to a class of medication called anticholinergics that work by blocking a certain natural substance (acetylcholine). This helps decrease muscle stiffness, sweating, and the production of saliva, and helps improve walking ability in people with Parkinson's disease. Anticholinergics can stop severe muscle spasms of the back, neck, and eyes that are sometimes caused by psychiatric drugs. It can also decrease other side effects such as muscle stiffness/rigidity (extrapyramidal signs-EPS). It is not helpful in treating movement problems caused by tardive dyskinesia and may worsen them. Benztropine should not be used by children younger than 3 years.

Invega Sustenna

Generic Formulation: Paliperidone PalmitateSpecialty: Psychiatry & Neurology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 532
UT State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills43.9
Peer Average Days Supply1,187
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.8% less volume than the regional standard for practitioners inside UT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $63,322.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,332.76

State Avg Cost Per Claim

$2,823.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.

Therapeutic Applications

Paliperidone is used to treat a certain mental/mood disorder called schizophrenia. This medication can decrease hallucinations, help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Paliperidone is an antipsychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This long-acting form of paliperidone is used only after you have received treatment with either the monthly injectable form of this drug for at least 4 months, or the every-3-month injectable form for at least 3 months.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ALISA BLOUNT VON RIOTTE MD provides transparency into local medical care patterns within Provo, UT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.